Preclinical studies have shown that eprenetapopt is efficient on its own, while it is also synergizing with AZA in TP53-mutated MDS and AML cell lines and in TP53-mutated cells from MDS and AML patients [75]. The gene discussed is TP53; the disease is acute myeloid leukemia.